- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Treatment with intranodal lymphangiography, ethiodized oil safe for postop chylothorax: Study
Leuven, Belgium: Intranodal lymphangiography (INL) with a high dose of ethiodized oil is safe and effective for the treatment of postsurgical refractory chylothorax with chest tube removal in 83% of patients, finds a recent study.
The findings of the study are published in the American Journal of Roentgenology (AJR).
"To our knowledge, no data are available on the safety or potential beneficial effect of injecting higher doses of ethiodized oil to treat patients with refractory postoperative chylothorax," wrote corresponding author Geert Maleux of University Hospitals in Leuven, Belgium.
All 18 patients (mean, 67 years; range, 43-76 years) the Belgian researchers reviewed between May 2015 and March 2019 had undergone INL with high doses of Guerbet's Lipiodol Ultra Fluid (mean, 75 mL; range, 40-140 mL). Eleven patients (61%) had previously undergone thoracic duct ligation, though seven (39%) had not, while lymphangiography confirmed lymphatic leak in 12 of 18 patients (67%).
For five of the 18 patients (28%), a second INL was performed within 11 days (range, 5-15 days)--due to increasing chest tube output after initiation of a medium-chain triglyceride-enriched diet--with three of the five (60%) showing complete resolution after the second session. Ultimately, removal of all chest tubes proved possible in 15 of 18 patients (83%) after a mean of 12 days (range, 1-25 days).
"Despite the doses being many times higher than the dose recommended by the manufacturer," the authors of this AJR article added, "no early or late clinically relevant complications, including symptomatic pulmonary or paradoxical embolism, were recorded for any of the patients."
"INL with a high dose of injected ethiodized oil is a safe and effective procedure for the management of postsurgical refractory chylothorax, with chest tube removal in 83% of patients," wrote the authors.
Reference:
The study titled, "Intranodal Lymphangiography With High-Dose Ethiodized Oil Shows Efficient Results in Patients With Refractory, High-Output Postsurgical Chylothorax: A Retrospective Study," is published in the American Journal of Roentgenology.
DOI: https://www.ajronline.org/doi/10.2214/AJR.20.23465
Hina Zahid Joined Medical Dialogue in 2017 with a passion to work as a Reporter. She coordinates with various national and international journals and association and covers all the stories related to Medical guidelines, Medical Journals, rare medical surgeries as well as all the updates in the medical field. Email:Â editorial@medicaldialogues.in. Contact no. 011-43720751
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751